KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

JERUSALEM and HOUSTON, Texas, Feb. 17, 2022 /PRNewswire/ — KAHR, a clinical stage oncology company developing novel dual-targeting fusion protein therapeutics, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.